An accomplished pharmaceutical executive, John Klein is the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to his responsibilities at Cambridge Therapeutics, John Klein is the chairman and CEO of the enterprise performance management (EPM) firm Bilogix.
Bilogix EPM services are run through Cognizant Business Consulting (CBC), the consulting division of Enterprise Analytics (EA). Cognizant makes use of a Four Aces framework for its EPM solutions. Four Aces implementation processes have been developed through the comprehensive six sigma business approach, as well as testing in various real-world scenarios. The framework accounts for all facets of EPM support and solutions, beginning with evaluating the client’s preparedness for EPM services.
Client readiness is tested through Cognizant’s customized SIMPOSM application. Following initial client engagement, the Four Aces Framework offers EPM services providers a platform from which to analyze specific industry needs and subsequently structure a unified set of solutions for all areas of need. Finally, the Four Aces Framework is rounded out by identification of the client’s preferred solution and strategies for a successful roll out.
The chairman of Cambridge Therapeutics, John Klein has facilitated FDA approval of more than 300 generic drugs throughout his extensive career in the pharmaceutical industry. John Klein is also the chairman and CEO of Bilogix, LLC, in Alpine, NJ.
Bilogix is an enterprise performance management (EPM) firm, meaning that it offers proprietary services designed to boost business clients’ operational performance and overall efficiency with an emphasis on information-technology infrastructure. EPM processes help measure, analyze, and estimate organizational performance and add value to businesses by directing the appropriate resources to achieve desired objectives. While EPM shares some commonalities with data processing tools like analytics and business intelligence (BI), they differ in their approach.
Most notably, BI and analytics tools focus on highlighting relevant information pertaining to daily operations so leaders can make informed decisions. In this way, they are generally reactive. Conversely, EPM tools are proactive. This is because they allow organizations to assess overall performance and make necessary changes based on information and data as it becomes available. Both BI and EPM have their benefits, and companies are increasingly leveraging both to track and refine operations.
Serving as the chairman of Cambridge Therapeutics in Alpine, NJ, John Klein has more than 20 years of experience in pharmaceutical manufacturing. In addition to leading Cambridge Therapeutics, John Klein functions as the chairman and CEO of Bilogix, an enterprise performance management (EPM) firm.
With a focus on helping business clients achieve maximum organizational efficiency and increase profits, Bilogix offers comprehensive analysis of operational data, as well as customized insights on improving business management. In today’s competitive business environment, EPM software and consulting services are considered necessary for organizations that want to boost their digital capabilities and remain profitable.
EPM analysis links financial data with performance metrics, which often reveals new strategies for generating revenue, as well as other steps for streamlining operations and cutting unnecessary costs. EPM solutions can also help managers and executives become more savvy as they use digital tools to monitor financial performance in real time and identify sales trends. Organizations of all types can benefit from an EPM solution in order to better understand their enterprise’s financial data and make more informed business decisions.
An experienced pharmaceutical executive based in Alpine, NJ, John Klein is the chairman of Cambridge Therapeutics. Credited with obtaining US Food and Drug Administration approval for over 300 generic drugs, John Klein remains up to date on health-related developments in NJ.
A new program based in Paterson, NJ, aims to improve health outcomes by offering affordable housing to people in need. In collaboration with the state, St. Joseph’s Health will provide increased aid to frequent visitors to its emergency departments by helping to transform a nearby parking lot into a first-of-its-kind affordable-housing development. The property site is located across the street from St. Joseph’s University Medical Center. When finished, it will have 70 residential units that include one- to three-bedroom apartments. Residents will be eligible for housing vouchers to subsidize their rent. The venture is part of the Hospital Housing Partnership Program, which will establish a support system to low-income individuals.
While most of the financing comes from St. Joseph’s, the Housing and Mortgage Finance Agency will provide $12 million in funding, and the New Jersey Development Corporation will manage the construction at the site. As of July 2019, eight other hospitals expressed interest in joining the Hospital Housing Partnership Program.
John Klein, the chairman of Alpine, NJ-based Cambridge Therapeutics, graduated from Roosevelt University with a bachelor of science and a master of business administration. Since then, he has led a successful career in the pharmaceutical industry that has culminated in several awards and repeated approvals from the Federal Drug Administration. At Cambridge Therapeutics, John Klein stays up to date on different medical challenges in his state.
In July 2019, Governor Phil Murphy signed a law that added New Jersey to a multistate nurse-licensing compact with 33 other states. The agreement is designed to help each of them address a nurse shortage. Prior to this action, it was predicted by federal reports that New Jersey would have the third most severe shortage problem in the country by 2030.
The measure was supported by many business leaders, nursing professionals, and lawmakers in the state. With the new legislation in place, healthcare institutions and hospitals in New Jersey have the option of hiring licensed practical nurses and registered nurses who have credentials in any of the other participating states, such as Maryland and Delaware. Similarly, these states are also free to recruit licensed nurses from New Jersey or other compact states.
Some nurse unions, however, have raised concerns about potential differences in regulatory structure between states. This unfamiliarity that a nurse might have with another state’s rules could lead to record-keeping errors and gaps in patient care. The New Jersey Board of Nursing also expressed reservations for the legislation, since it tasks the board with managing the program without granting the organization any additional resources.
New Jersey-based executive John Klein serves as the chairman of Cambridge Therapeutics. In addition to overseeing operations at Cambridge Therapeutics, John Klein takes an active interest in developments concerning health care and health policy.
New Jersey officials announced new rules intended to expand access to the state’s medical marijuana program, following the directive set in an executive order by Governor Phil Murphy. In addition to removing bureaucratic hurdles for young patients, the new policies will allow patients with a wider variety of diseases and ailments to access medical marijuana.
Taking effect May 20, 2019, the reforms also relax some of the regulations governing businesses that grow, produce, and sell medicinal cannabis. Other policies already in effect but now codified include reducing medical cannabis costs for patients and permitting doctors to prescribe medical marijuana without being named publicly as a physician participating in the program.
An accomplished pharmaceutical executive, John Klein leads New Jersey-based Cambridge Therapeutics as chairman. Aside from steering the development of Cambridge Therapeutics, John Klein maintains an active interest in following health-related developments impacting residents of New Jersey and beyond.
New Jersey Governor Phil Murphy recently signed a package of bills aimed at reducing the state’s extremely high maternal mortality rate. In particular, the bills aim to address racial disparities in health care: throughout the nation, African American mothers are more than four times more likely than white women to die of complications related to pregnancy, childbirth, or postpartum recovery. “In a state that is among the very wealthiest in our nation,” said Governor Murphy, “these disparities stand in stark contrast to our core values.”
The bill signings occurred one day after the Centers for Disease Control and Prevention released a report concluding that nearly half of pregnancy-related deaths are preventable. One provision in the newly signed New Jersey bills requires Medicaid to cover doula services, a birth support role that has been shown to improve birth outcomes. Another provision discourages the scheduling of cesarean sections before the baby is full term out of convenience rather than necessity.
Cambridge Therapeutics founder and chairman John Klein directs the innovative work of a Teaneck, New Jersey-based team dedicated to producing next-generation medical devices and health care products. Outside of his pursuits with Cambridge Therapeutics, he supports nonprofit organizations focused on health care, education, and the public good. John Klein also serves as a trustee with Hackensack Meridian Health Hospitals, a network that consistently receives high rankings for its quality of care.
In 2018, the local news outlet NJ.com amplified a report analyzing the safety of hospitals nationwide and noting how the medical facilities in New Jersey had ranked. The NJ.com article’s lead noted the good news that New Jersey’s hospitals as a group earned more top ratings for safety than the hospitals of any other state.
Thirty-eight of the 67 New Jersey hospitals surveyed – including eight facilities in the HMH network – received a grade of “A.”
Produced under the branding of the Leapfrog Hospital Safety Grade organization, the report was six years in the making, as an expert panel evaluated hospitals in terms of their ability to keep patients secure from infections, injuries, and staff errors.
Among the other recent accolades that HMH has received is a 2018-19 U.S. News & World Report ranking as one of the state’s two best hospitals overall.
John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. In addition to his pursuits with Cambridge Therapeutics, John Klein serves as a member of the Board of Trustees of Hackensack Meridian Health Hospitals and keeps apprised of developments in the state of health care in his region through various news outlets.
In April 2019, NJSpotlight’s online “Healthcare” section summarized a major new report on the health care landscape in New Jersey that additionally offered insights into the best ways for the state’s policymakers to improve the quality and equitable delivery of medical care.
Entitled “Building a Culture of Health,” this report was created with support from the Robert Wood Johnson Foundation and Rutgers University.
It notes that, despite New Jersey’s advances in providing strong family leave programs for workers, high-quality early childhood education, and public education campaigns that have helped reduce smoking rates, a disturbing number of disparities in health care distribution remain across ethnicity, income, geography, and social class. The report estimates that close to 6,500 people die needlessly in the state every year due to such barriers to access.
The report consists of more than one dozen specific recommendations to officials planning health care policy, urging them to fund targeted improvements. The first item on the list involves upgrading the quality of maternal and infant care. Others given high priority include strengthening overall community health by ensuring that at-risk families can access quality housing, education, and paid family leave benefits.
With more than three decades of experience as a healthcare and pharmaceutical executive, John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. During his six-year service as the CEO of Cambridge Therapeutics, John Klein developed knowledge of the Food and Drug Administration’s Code of Federal Regulations, as well as rules enacted by the State of New Jersey.
The New Jersey Department of Human Services (NJDHS) continues to make changes to state policy to ensure Medicaid patients have access to effective therapies for substance-abuse disorders. As of March 31, 2019, the state’s 1.7 million Medicaid enrollees are no longer required to gain approval from the managed-care plan that administers their insurance benefits before receiving medication-assisted treatment (MAT) for opiate addiction.
Viewed as the gold-standard for addressing opiate dependency, MAT involves prescribing patients opioid-replacement medications to minimize withdrawal symptoms and help calm addictive behaviors. In addition to assisting to eliminate insurance hurdles for state Medicaid enrollees, the NJDHS released new rules mandating all addiction-treatment facilities with such patients to offer MAT as a treatment option, effective July 1, 2019.